Results 91 to 100 of about 15,943 (150)

Real-Life Use of Subcutaneous Biologicals and JAK Inhibitors in IBD Maintenance Therapy: Treatment Continuation, Switching Patterns, and Concomitant Medications. [PDF]

Clin Exp Gastroenterol
Koivusalo M, Jokelainen J, Huhtinen A, Kovac B, Silvola S, Torvinen S, Ylisaukko-Oja T, Arkkila P.   +7 more
europepmc   +1 more source

Risankizumab redefines Crohn's treatment after ustekinumab failure. [PDF]

World J Gastrointest Pharmacol Ther
Omullo FP.
europepmc   +1 more source

Dendritic cell-T cell circuitry in health and changes in inflammatory bowel disease and its treatment

, 2015
Knight, SC
core   +1 more source

Vedolizumab in inflammatory bowel disease: pharmacokinetics and the role of immunomodulator co-therapy. [PDF]

Ther Adv Gastroenterol
Pudipeddi A, Chaemsupaphan T, Arzivian A, Kim YS, Paramsothy S, Kariyawasam V, Leong RW.   +6 more
europepmc   +1 more source

Evaluating treatment to a target of transmural healing in patients with moderately to severely active Crohn's disease: rationale, design and protocol for the randomised controlled VECTORS trial. [PDF]

BMJ Open Gastroenterol
Jairath V, Vuyyuru SK, Zou G, Ma C, Neustifter B, Agboton C, Romo Bautista I, Allocca M, An YK, Begun J, Bryant RV, Danese S, Dubinsky M, Feagan BG, Freire M, Novak KL, Panaccione R, Pudipeddi A, Rubin DT, Sands BE, Sparrow MP, Taylor SA, Gecse KB, Wilkens R, Maaser C.   +24 more
europepmc   +1 more source

Physiologically Motivated Sequential Population Modeling of Albumin Trends and Vedolizumab Pharmacokinetics for Pregnancy Dosing Regimen Optimization. [PDF]

Clin Pharmacol Ther
Duvnjak Z, Michelet R, Steenholdt C, Widigson ESK, Skejø C, Abrantes JA, Huisinga W, Julsgaard M, Kloft C.   +8 more
europepmc   +1 more source

Comment on: “Forecasting Pharmaceutical Prices for Economic Evaluations When There is No Market: A Review” [PDF]

, 2017

core   +1 more source

Real-world effectiveness of vedolizumab in refractory pouchitis: a focus on biomarker changes during intravenous to subcutaneous transition (POUCHIVED study). [PDF]

Front Immunol
Gimeno-Pitarch L, Céspedes-Martínez E, Ferreiro-Iglesias R, Martín-Arranz MD, Sicilia B, Lorca I, Huguet J, Mesonero F, Vicente-Lidón R, Mínguez A, Galvez-Martín P, Serra-Ruiz X, Barreiro-de Acosta M, Nos P, Iborra M.   +14 more
europepmc   +1 more source

Cost-effectiveness of different strategies with biologics for the treatment of moderate to severe Crohn's disease in China. [PDF]

World J Gastroenterol
Wu Y, Tao LB, Liu C, Wang FX, Yan Y, Sun S.   +5 more
europepmc   +1 more source

Higher Vedolizumab Clearance Associates with Poor Therapeutic Outcomes during Intravenous Vedolizumab Maintenance Therapy in Crohn's Disease. [PDF]

Inflamm Bowel Dis
Anjie SI, D'Haens GR, Baert F, Bossuyt P, Hoentjen F, Clasquin E, Molnár T, Löwenberg M, Vermeire S, Panetta JC, Dervieux T.   +10 more
europepmc   +1 more source